1952-53

Mental (i.e., antidepressive) effects of iproniazid (an MAOI), initially developed and used for its tuberculostatic properties, first noted by several investigators. By 1956, mental side effects of iproniazid caused it to fall out of favor in treatment of TB (Healy, I, 61-63).